What this study is
This pilot study will evaluate communication strategies that may improve public understanding of alcohol-related cancer risks and influence behavioral intentions. The study will compare graphic alcohol cancer warning labels with the current U.S. Surgeon General text-only warning label across two stages. The first stage is an in-person, lab-based eye-tracking experiment that will examine differences in visual attention, communication outcomes, harm perception, and behavioral intentions following exposure to graphic versus text-only warning labels. The second stage is a discrete choice experiment that will examine how warning label type, warning label size, and alcohol type (beer, wine, or liquor) influence participants' intentions to reduce or stop alcohol consumption and purchase alcohol. The study will recruit 50 adults aged 21 years or older who report regular alcohol consumption.
What's being tested
- Alcohol Cancer Warning Labels
Intervention · BEHAVIORAL
Participants will be exposed to alcohol-cancer warning labels during two sequential study states. Stage 1 consists of Eye-Tracking Experiment in which participants will be exposed to six alcohol warning-label stimuli, including graphic alcohol cancer warning labels and Surgeon General text-only warning labels displayed on beer, wine, and liquor containers. Each participant will view all six warning-label stimuli for 15 seconds each in a randomized, counterbalanced order while visual attention is measured using eye-tracking technology. Stage 2 consist of the Discrete Choice Experiment in which participants will choose between 18 randomly presented choice sets. Choice sets will vary by warning label type, warning label size, and alcohol type (beer, wine, or liquor). Participants' responses will be used to assess preferences and behavioral reactions to different alcohol warning-label characteristics.
Study details
- Official title
- Eye-Tracking and Discrete Choice Experiments Testing Alcohol Cancer Risk Warning Labels: Implications for Policy
- Sponsor
- University of Miami
- Conditions
- Alcohol
- Enrolling
- 50 people
- Starts
- 2026-11
- Est. completion
- 2027-10-01
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 21 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age ≥ 21 years
- Regular alcohol consumers (≥ 2 drinks per week)
- US residence
- Able to read and understand English
- Able and willing to provide informed consent
- Able to wear eyeglasses
You can't join if
- Are not regular alcohol consumers (< 2 drinks per week)
- Are unable to complete study procedures due to cognitive or physical limitations
- Decline or withdraw informed consent
- Pregnant women, prisoners, persons not residing in the US, and non-alcohol users
- Have eye conditions or impairments that prevent reliable eye-tracking (e.g., severe nystagmus or uncorrectable visual impairment)
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Miami - Rosenstiel Medical Science Building
Miami, Florida, United States
- Taghrid Asfar, Principal Investigator, MD, MPH · Contact305-243-3826tasfar@miami.edu
- Maria Fernanda Garcia Morillo, B.S. · Contact5615697987mfg136@med.miami.edu
- Olusanya Oluwole · Sub-investigator
Study team
Sponsor
University of Miami
Study ID 20260643
Principal investigator
Taghrid Asfar, MD, MSPH
University of Miami
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.